Stringent Hepatic Monitoring Urged For Diabetes Drug Clinical Trials

Difficulties surrounding the assessment of a possible case of drug-induced liver injury in the dapagliflozin clinical program show why more standardized hepatic monitoring is needed in future studies of type 2 diabetes agents, one of FDA’s outside advisors said.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet